Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced Leukemias
Status:
Completed
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine the maximum tolerated dose, dose limiting
toxicity, safety and tolerability of TH-302 in patients with acute leukemias, advanced phase
chronic myelogenous leukemia (CML), high risk myelodysplastic syndromes, advanced
myelofibrosis or relapsed/refractory chronic lymphocytic leukemia (CLL).